Radicava (edaravone) approved for ALS by FDA

What is Radicava? Do you remember the Ice Bucket Challenge, the challenge that carried out by most famous people and passed to others as an awareness campaign for amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig’s disease.

Amyotrophic lateral sclerosis (ALS)

ALS is a rare disease that attacks and kills the nerve cells that control voluntary muscles. Voluntary muscles produce movements such as chewing, walking, breathing and talking. The nerves lose the ability to activate specific muscles, which causes the muscles to become weak and leads to paralysis. ALS is progressive, meaning it gets worse over time.

Radicava (edaravone)

Radicava is an intravenous infusion given by a health care professional. It is administered with an initial treatment cycle of daily dosing for 14 days, followed by a 14-day drug-free period. Subsequent treatment cycles consist of dosing on 10 of 14 days, followed by 14 days drug-free.

The most common adverse reactions reported by clinical trial participants receiving edaravone were bruising (contusion) and gait disturbance.

Company:

Mitsubishi Tanabe Pharma America, Inc.

By the way here is a video of Donald Trump ALS Ice Bucket Challenge:

source:

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm557102.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery